Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

This trial is open and accepting eligible patients.

Trial Overview

This phase I trial studies the side effects and best dose of leflunomide in treating patients with multiple myeloma that has come back (recurrent) or has not responded to previous treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

What is the phase of this trial?

Phase 1 what does this mean

What type of trial is this?

This is an interventional trial. This type of trial actively treats your myeloma.

What treatments are used in this trial?
  • Leflunomide
Trial Locations

There are 1 trial site around the United States.
Find the closest trial site.

How many patients will participate in this trial?

Approximately 42 patients will be enrolled in this study.

Who is sponsoring this trial?

City of Hope Medical Center

SparkCures Trial Identifiers

MM-0745 , NCT02509052 what is this

1 US location

Am I Eligible For This Trial?

All clinical trials provide reasons that patients may or may not be able to join called 'eligibility criteria'. The following is a high-level eligibility criteria provided by the sponsor of this trial. Additional eligibility criteria may apply.

Trial Contact Information

For study information, please contact Michael Rosenzweig at (626) 256-4673 or mrosenzweig@coh.org.

Trial locations are sorted by state. Enter your zip code to sort by closest distance.


City of Hope Comprehensive Cancer Center

(Beckman Research Institute)

1500 East Duarte Road, Duarte, CA 91010

This site is open and accepting eligible patients.

There is 1 active US location.